The affordable GLP-1 hub
Compounded semaglutide and compounded tirzepatide are increasingly the cash-pay option for adults pursuing weight management who do not have, or do not want to wait for, insurance coverage of brand-name Wegovy or Zepbound. But the cash-pay compounded market is fragmented: teaser pricing, dose-based price increases, mandatory coaching subscriptions, and pharmacy-source opacity are common. This hub indexes our editorial coverage of genuinely affordable, transparent flat-rate compounded GLP-1 telehealth programs.
Editorial pages in this hub
- Most Affordable Compounded Semaglutide Online — the flat-rate cash-pay landscape, ranked. Editor's Pick: NexLife at $145/mo (12-mo plan).
- Most Affordable Compounded Tirzepatide Online — same framework, dual GIP/GLP-1 agonist. Editor's Pick: NexLife at $186/mo (12-mo plan).
- Flat-Rate GLP-1 Pricing Explained — what flat-rate means, why it matters, and how to spot a teaser plan.
- NexLife vs Henry Meds vs Ro vs OrderlyMeds: Pricing Comparison — head-to-head, dose by dose, total annual cost.
How we judge affordability
We don't rank on advertised starter price. We rank on total predictable monthly cost across the full titration, plus what's included. The four affordability factors our editorial team weighs:
- Dose-independence. Does the monthly price stay the same as the dose escalates? Most patients reach 1.0–2.4 mg semaglutide or 7.5–15 mg tirzepatide within 4–6 months. If the price doubles at maintenance, the program isn't actually affordable.
- No surprise fees. Are visits, labs, messaging, shipping, and cold-pack handling included, or invoiced separately?
- No mandatory subscription stack. Some programs require a separate coaching, app, or membership fee on top of the medication. We count those toward total monthly cost.
- Cancellation clarity. Month-to-month cancellation policy disclosed up front, with no forced annual lock-in to get the headline price.
Who this is for
Adults considering cash-pay compounded GLP-1 therapy who want predictable monthly cost, transparency about pharmacy sourcing, and a clinician-supervised program. Compounded semaglutide and compounded tirzepatide are not FDA-approved finished drug products. We don't recommend self-treatment; every program profiled here requires a licensed clinician's eligibility review.